Quick Answer
Ocean Biomedical, Inc. reported Net Income Loss of -$9.48 million for the year ending 2024.
- Ocean Biomedical, Inc. showed an increase of +91.7% in Net Income Loss from 2023 to 2024.
- This data is from Ocean Biomedical, Inc.'s annual report (Form 10-K), filed with the SEC on April 8, 2025.
- XBRL data for this metric is available from 2022 to 2024 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: -$82.00 | Q3 2021: -$42.5 thousand | Q1 2022: -$5.38 million | Q2 2022: -$7.33 million | Q3 2022: -$3.67 million | Q1 2023: -$72.09 million | Q2 2023: -$11.43 million | Q3 2023: -$14.09 million | Q1 2024: $13.00 million | Q2 2024: -$17.23 million | Q3 2024: -$3.70 million | Q1 2025: -$8.24 million.
- Over the full 3 years of available data (2022 to 2024), Ocean Biomedical, Inc.'s Net Income Loss has grown by 45.4%.
- Historical annual values: Fiscal year 2024: -$9.48 million | Fiscal year 2023: -$114.47 million | Fiscal year 2022: -$17.36 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: